Stemcell Holdings, Inc. (STMM)
Stemcell Holdings, Inc. operates in the Biotechnology industry of the Healthcare sector, headquartered in Tokyo, JP. The stock last traded at $0.06, down 0.00% on the session, giving a market capitalisation of $1.6M. On trailing twelve-month figures it carries a trailing P/E of 0.69, a net margin of 39.0%. Its beta of 0.00 implies it has historically moved less than the broad market.
Stemcell Holdings, Inc., primarily operating through its subsidiary Stemcell Co., Ltd., specializes in the regenerative medicine sector. The company provides crucial technical support for the cultivation, storage, and delivery of stem cells, alongside administrative and consulting services for clinics. It offers two distinct stem cell regenerative therapies: autologous mesenchymal stem cells derived from adipose tissue and natural killer cells. To facilitate its stem cell culturing activities, Stemcell Holdings coordinates patient introductions to clinics, manages scheduling, and provides translation services to overcome language barriers between patients and medical professionals. Additionally, the firm offers internet marketing solutions, specifically search engine optimization for clinics, and engages in property and equipment rental. Founded in Tokyo, Japan, in 2015, the company was formerly known as Perfect Acquisition, Inc. before changing its name to Stemcell Holdings, Inc. in January 2016. As of May 2, 2016, Stemcell Holdings, Inc. operates as a subsidiary of Primavera Singa Pte Ltd.
Stemcell Holdings, Inc. is most often compared with the following Healthcare names: